The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).
 
Catherine Curran
No Relationships to Disclose
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Consulting or Advisory Role - Bayer; Takeda
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Xiao X. Wei
Honoraria - OncLive
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Kerry L. Kilbridge
No Relationships to Disclose
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
Praful Ravi
No Relationships to Disclose
 
Arvind Ravi
Employment - Halo Pharma
Leadership - Halo Pharma
Stock and Other Ownership Interests - Halo Pharma
Consulting or Advisory Role - Halo Pharma
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis
Speakers' Bureau - Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; QED Therapeutics